Inagaki Masaharu, Ichimura Hideo, Usui Shingo, Iguchi Kesato, Ishibashi Osamu, Nakamura Ryota, Inage Yoshihisa, Suzuki Hisashi, Kiyoshima Moriyuki, Kamiyama Koichi, Kimura Masaki, Yoshida Susumu, Sakai Mitsuaki, Kobayashi Naohiro, Furukawa Kinya, Satoh Hiroaki, Hizawa Nobuyuki, Sato Yukio
Department of Thoracic Surgery, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki 3000028, Japan.
Divisions of Thoracic Surgery, Hitachi General Hospital, Hitachi, Ibaraki 3170077, Japan.
Mol Clin Oncol. 2021 Jan;14(1):11. doi: 10.3892/mco.2020.2173. Epub 2020 Nov 19.
The present study aimed to evaluate clinical outcomes in patients with surgically resected non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-rearranged mutations. A matched-pair analysis in completely resected ALK-rearranged NSLC patients and those with neither ALK nor epidermal growth factor receptor (EGFR) mutations diagnosed at 11 institutes was performed between April 2008 and March 2019. A total of 51 patients with surgically resected ALK-rearranged NSCLC were included. Women constituted 68.6%, and smokers 29.4%. The median age was 65 years. In matched-pair analysis, disease-free survival and overall survival did not differ between patients with ALK-rearranged mutations and those without mutations. Post-recurrence survival in patients with ALK mutations was longer than that of patients with neither ALK nor epidermal growth factor receptor mutations. ALK genetic testing should be performed, even in elderly patients with NSCLC. Favorable prognosis might be expected after appropriate treatment for patients with recurrent ALK-mutated disease.
本研究旨在评估手术切除的间变性淋巴瘤激酶（ALK）重排突变的非小细胞肺癌（NSCLC）患者的临床结局。2008年4月至2019年3月期间，在11家机构对完全切除的ALK重排NSLC患者以及未诊断出ALK和表皮生长因子受体（EGFR）突变的患者进行了配对分析。总共纳入了51例手术切除的ALK重排NSCLC患者。女性占68.6%，吸烟者占29.4%。中位年龄为65岁。在配对分析中，ALK重排突变患者和无突变患者的无病生存期和总生存期没有差异。ALK突变患者的复发后生存期比既无ALK也无表皮生长因子受体突变的患者更长。即使是老年NSCLC患者，也应进行ALK基因检测。对于复发的ALK突变疾病患者，经过适当治疗后可能预期有良好的预后。
